The presence of antiarrestin autoantibodies among patients with SLE is associated with an increased risk of developing HCQ-related retinal toxicity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback